Study identifier:D3465C00004
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
A Randomized, Phase I, Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Subcutaneously and Intravenously Delivered Anifrolumab in Healthy Chinese Participants
Healthy Volunteers
Phase 1
Yes
Anifrolumab
All
24
Interventional
18 Years - 55 Years
Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment
Verified 01 Sept 2024 by AstraZeneca
AstraZeneca
-
No locations available
Arms | Assigned Interventions |
---|---|
Experimental: Subcutaneous | Drug: Anifrolumab Participants will receive a single SC or IV dose of anifrolumab at day 1 Other Name: Saphnelo |
Experimental: Intravenous | Drug: Anifrolumab Participants will receive a single SC or IV dose of anifrolumab at day 1 Other Name: Saphnelo |